NCT00593463View on ClinicalTrials.gov

Drug Discrimination in Methadone-Maintained Humans Study 1

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Drug Dependence
Interventions
DRUG

Cycloserine

Cycloserine: 500, 675, 750 mg oral capsule may possibly be given

DRUG

Diltiazem

Diltiazem: 30, 60, 120 mg oral capsule may possibly be

DRUG

Gabapentin

Gabapentin: 100, 200, 400 mg oral capsule may possibly be given

DRUG

Isradipine

Isradipine: 5, 10 mg oral capsule may possibly be given

DRUG

Naloxone

Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given

DRUG

Nifedipine

Nifedipine: 5, 10, 20 mg oral capsule may possibly be given

DRUG

Placebo

Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given

DEVICE

Saline

Saline: I.M. injection may possibly be given

DRUG

Verapamil

Verapamil: 30, 60, 120 mg oral capsule may possibly be given

Trial Locations (1)

72205

University of Arkansas for Medical Sciences, Little Rock

All Listed Sponsors
lead

University of Arkansas

OTHER

NCT00593463 - Drug Discrimination in Methadone-Maintained Humans Study 1 | Biotech Hunter | Biotech Hunter